The work addresses a long-standing challenge in cancer therapy: how to make powerful treatments concentrate inside tumors while limiting damage to healthy tissues. Attenuated strains of Salmonella have attracted interest because they can preferentially accumulate in the abnormal environment of solid tumors. Tumors often contain regions with poor oxygen levels, disorganized blood vessels and local immune suppression, conditions that can support bacterial growth. Once inside these sites, therapeutic Salmonella can act as a biological delivery platform and stimulate immune responses against malignant cells.

The researchers focused on calreticulin, a protein normally found inside the endoplasmic reticulum, where it helps regulate calcium storage and protein folding. Under cellular stress, including stress caused by chemotherapy, radiation or other anticancer treatments, calreticulin can move to the outer surface of a cancer cell. There, it functions as an “eat-me” signal, alerting immune cells that the damaged cell should be engulfed. Because surface-exposed calreticulin is associated with immunogenic forms of cell death, it provides a potential molecular address for directing therapeutic agents toward stressed tumor cells.

The experimental construct combines this targeting concept with L-asparaginase, an enzyme already used in clinical oncology, especially in the treatment of acute lymphoblastic leukemia. L-asparaginase breaks down circulating L-asparagine into aspartic acid and ammonia. Some cancer cells, particularly those with limited capacity to synthesize their own asparagine, depend heavily on the amino acid supplied through the bloodstream. Depleting extracellular asparagine can therefore interrupt protein production, trigger metabolic stress and promote cancer-cell death. The enzyme’s effectiveness, however, can be limited by immune reactions, pharmacological instability and toxicity, making targeted delivery an important goal.

The second component, flagellin, is the structural protein that forms the filament of bacterial flagella. It is also a potent molecular signal for the innate immune system. Immune cells recognize flagellin primarily through Toll-like receptor 5, while intracellular sensing pathways can activate inflammasome components such as NLRC4. These signals can promote the release of inflammatory mediators, stimulate antigen-presenting cells and help convert an immunologically “cold” tumor into one more visible to the immune system. By incorporating flagellin into the therapeutic design, the researchers sought to make the treatment not only directly toxic to tumor cells but also capable of amplifying antitumor immunity.

The study’s central finding was that the calreticulin-targeting L-asparaginase–flagellin conjugate strengthened the antitumor effects of Salmonella-based therapy. Rather than relying on a single mechanism, the treatment brings together several forms of pressure on the tumor. Salmonella can concentrate within the tumor microenvironment, the targeting component can help associate the conjugate with calreticulin-exposing cancer cells, L-asparaginase can deprive vulnerable cells of an essential nutrient, and flagellin can activate immune surveillance. The resulting combination is designed to produce a chain reaction in which metabolic stress and immune stimulation reinforce one another.

This type of combination may be particularly valuable because tumors frequently adapt when exposed to one therapeutic pressure. A cancer cell that survives nutrient deprivation may still be eliminated if immune recognition is intensified. Likewise, an immune response that is too weak to control a tumor may become more effective when bacterial localization and enzyme-mediated damage increase the number of abnormal antigens and danger signals released by dying cells. The researchers’ findings suggest that coordinating these mechanisms can improve the performance of bacteria-assisted cancer treatment in experimental settings.

The approach also reflects a broader shift in cancer research toward programmable biological medicines. Instead of treating bacteria only as infectious threats, scientists are redesigning them as localized delivery vehicles capable of carrying enzymes, immune activators or molecular probes. The advantage is spatial: a therapeutic payload can be produced or concentrated near the tumor rather than distributed uniformly throughout the body. The challenge is equally significant. Any clinical version would need precise control over bacterial attenuation, immune activation, enzyme exposure and potential inflammation, while also demonstrating reliable performance across genetically diverse tumors.

Calreticulin targeting may provide a useful way to address some of that complexity because the protein’s appearance on the cell surface is linked to cellular stress and treatment response. However, the extent and duration of calreticulin exposure can vary between tumor types and individual patients. Future studies will need to determine which cancers are most suitable for this strategy, how calreticulin levels predict treatment response and whether the conjugate can be combined safely with established immunotherapies such as immune-checkpoint inhibitors. Researchers will also need to assess pharmacology, manufacturing consistency and the possibility of immune reactions against the bacterial or enzymatic components.

The findings position the engineered conjugate as a promising experimental platform rather than an immediately available therapy. By merging tumor-homing bacteria with a calreticulin-directed enzyme and an innate immune stimulant, the study illustrates how cancer treatments can be designed to attack malignant cells on multiple biological fronts. If the results are confirmed in further preclinical testing and eventually in carefully controlled clinical trials, this strategy could help turn Salmonella from a passive carrier into an active, multifunctional partner in cancer immunotherapy.

Subject of Research: Calreticulin-targeted L-asparaginase–flagellin conjugate used with Salmonella-mediated cancer therapy.

Article Title: Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy.

Article References: Nguyen, DH., Afzal, A.R., Nguyen, P.TM. et al. Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03300-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03300-x

Keywords: cancer immunotherapy, Salmonella, calreticulin, L-asparaginase, flagellin, tumor targeting, bacterial therapy, antitumor efficacy, immunogenic cell death

Central to recent advancements in reversing immune evasion within tumors is the cyclic GMP-AMP synthase (cGAS) – stimulator of interferon genes (STING) pathway. This innate immune sensing mechanism detects cytosolic DNA damage characteristic of malignancies, subsequently initiating a cascade culminating in the production of type I interferons such as interferon-beta (IFN-β). These molecular signals activate dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs), key players in orchestrating an effective antitumor immune response. However, pharmacologic modulation of the cGAS-STING axis for HCC therapy remains in its infancy, with few agents demonstrating robust clinical potential to date.

In a groundbreaking study, a research consortium spearheaded by Dr. Zhuo Yu at Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, alongside Prof. Jianfeng Guo from Jilin University, unveiled an innovative nanoparticle-based strategy to enhance cGAS-STING pathway activation in HCC. Their approach ingeniously co-delivers two pharmacologically distinct agents: melarsoprol (MEL), a drug shown to stimulate the cGAS-STING immune cascade, and lenalidomide (LEN), an immunomodulatory drug famed for its tumor necrosis factor-alpha (TNF-α) antagonism. By uniting these agents within a novel delivery system, the team sought to harness synergistic effects while blunting deleterious inflammatory responses.

The rationale for this combinatorial therapy rests on a nuanced understanding of the immune milieu within HCC. While melarsoprol robustly triggers the cGAS-STING pathway, inducing potent antitumor immunity, it concurrently induces an overproduction of TNF-α, a pro-inflammatory cytokine known to exacerbate tumor progression and immune escape. Lenalidomide, conversely, modulates the tumor-promoting effects of TNF-α without dampening the beneficial interferon-driven immune activation. Through this dual modulation, the therapy aims to create an immunological environment conducive to tumor eradication.

Crucially, the delivery vehicle for this drug combination is itself a marvel of biomedical engineering. The team engineered poly(lactic-co-glycolic acid) (PLGA) nanoparticles cloaked with erythrocyte membranes, functionalized with an AEAA-targeting moiety to ensure specific uptake within the tumor microenvironment. This erythrocyte membrane coating confers biocompatibility and immune evasion capabilities to the nanoparticles, prolonging circulation half-life and enhancing tumor targeting. Moreover, the system features acid-responsive drug release triggered by the acidic conditions characteristic of the TME, ensuring precise payload delivery and minimizing off-target toxicity.

In vivo experiments utilizing murine models of hepatocellular carcinoma demonstrated remarkable therapeutic outcomes. Mice treated with the MEL-LEN nanoparticle formulation exhibited significant tumor shrinkage, heightened infiltration of immune effector cells such as CTLs and DCs, and prolonged survival rates compared to controls receiving monotherapies or placebo. Importantly, this potent antitumor effect was achieved without visible systemic toxicity or adverse effects on normal tissues, marking a significant advancement over conventional chemotherapeutics.

Mechanistic investigations revealed that melarsoprol induced strong activation of the cGAS-STING pathway, resulting in elevated secretion of type I interferons and subsequent priming of adaptive immune responses. However, the induced TNF-α surge was curbed effectively by lenalidomide co-delivery, mitigating tumor-supportive inflammation and preventing immune suppression. This delicate immunologic balance underscores the importance of combinatorial immunomodulation strategies over singular drug interventions.

The authors emphasized the translational potential of this nanomedicine platform, citing its modular design capable of accommodating various drug combinations tailored to specific tumor immunobiology profiles. Furthermore, the erythrocyte membrane coating serves as an elegant natural camouflage, addressing critical challenges in nanoparticle delivery such as rapid clearance by the mononuclear phagocyte system and nonspecific uptake by healthy organs.

Looking forward, Dr. Yu and Prof. Guo’s team plans to propel this promising nanoparticle formulation into early-phase clinical trials, aspiring to validate its safety and efficacy in human patients afflicted with HCC. They also envision integrating this therapy with immune checkpoint inhibitors—agents that have revolutionized cancer therapy in recent years—to amplify antitumor immune responses further and overcome residual resistance mechanisms. Such combinational regimens could redefine therapeutic paradigms in liver cancer, a traditionally intractable malignancy.

This study not only elucidates the intricate interplay between innate immune activation and inflammatory regulation within the tumor microenvironment but also exemplifies the transformative power of nanotechnology in precision oncology. By addressing multiple facets of tumor immunology concurrently, this nanoparticle-enabled chemoimmunotherapy sets a new standard for rational drug design aimed at overcoming immune evasion and enhancing therapeutic outcomes in hepatocellular carcinoma.

This pioneering work, published in Fundamental Research, represents a critical milestone in our ongoing quest to ‘unlock’ the liver’s immunosuppressive barrier, converting it from a sanctuary for cancer cells into a battleground for effective antitumor immunity. Through sophisticated biomimetic design and insightful immunopharmacology, the research heralds a future where durable remission and improved survival for HCC patients become attainable realities rather than aspirational hopes.

Subject of Research: Animal tissue samples

Article Title: Lenalidomide promotes melarsoprol-activated cGAS-STING-mediated immunotherapy for hepatocellular carcinoma via attenuating TNF-α activity

Web References: http://dx.doi.org/10.1016/j.fmre.2023.05.013

Image Credits: Yu Z, Zou Y F, Han S L, et al.

Keywords: Hepatocellular carcinoma, cGAS-STING pathway, Immunotherapy, Nanoparticles, Melarsoprol, Lenalidomide, Tumor microenvironment, TNF-α, Chemotherapy, Drug delivery, Biomedical engineering, Acid-responsive release

At the heart of neoantigen-based immunotherapy lies the immune system’s remarkable ability to distinguish abnormal cells from healthy tissue. This recognition centrally involves the presentation of neoantigens on the surface of tumor cells via Major Histocompatibility Complex (MHC) molecules. When displayed effectively, these neoantigens enable cytotoxic T cells to identify and eliminate malignant cells. However, successful activation of T cells not only depends on antigen presentation but also requires intricate co-stimulatory signals delivered by antigen-presenting cells, notably dendritic cells. The interplay of these elements forms the basis of the immune system’s antitumor response, which researchers are keen to enhance through targeted interventions.

In recent years, the field of computational biology has witnessed rapid advancements that dramatically improve the prediction and identification of neoantigens. Bioinformatics tools leverage high-throughput sequencing data to detect somatic mutations—the genetic alterations specific to tumor cells—and subsequently predict the peptides capable of binding to a patient’s MHC molecules. These algorithms assess binding affinities and immunogenic potential, helping scientists prioritize neoantigens most likely to elicit strong immune responses. This methodical selection process is vital for designing effective personalized cancer vaccines and T cell therapies with maximal specificity and minimal off-target effects.

A cornerstone in neoantigen discovery is the accurate determination of an individual’s Human Leukocyte Antigen (HLA) haplotype, which dictates the MHC molecule repertoire. Traditional techniques are often costly and resource-intensive, but computational haplotyping methods offer a cost-effective alternative by analyzing sequencing data to infer HLA types. These advances democratize access to personalized immunotherapies by reducing logistical barriers and accelerating the timeline from sample collection to neoantigen identification. Improved HLA typing enhances the precision of neoantigen prediction pipelines, facilitating tailored immunotherapeutic interventions.

Nevertheless, the computational prediction of neoantigens alone is insufficient, as the immunopeptidome—the actual collection of peptides presented by MHC molecules on tumor cells—can differ from predicted sequences. This has driven the integration of proteogenomics, a multidisciplinary approach combining genomic, transcriptomic, and proteomic data to validate neoantigen presentation experimentally. Immunopeptidomics, which directly identifies MHC-bound peptides via mass spectrometry, confirms the natural processing and presentation of predicted neoantigens. This crucial step adds an empirical layer of confidence, ensuring that therapeutic strategies target epitopes genuinely displayed by cancer cells.

The synergy between computational algorithms and proteogenomic validation reshapes the landscape of neoantigen research. Using multiple layers of molecular data not only refines neoantigen selection but also enhances the overall reliability of personalized cancer vaccines and cellular therapies. This integrative approach addresses challenges such as tumor heterogeneity and immune evasion, which complicate treatment efficacy. It embodies a shift toward precision oncology, where therapies are custom-designed based on the unique molecular fingerprint of each patient’s tumor.

Clinical trials have begun to harness these technological advancements, translating neoantigen predictions into therapeutic realities. Early-phase studies on neoantigen vaccines demonstrate encouraging immunogenicity and safety profiles, underlining the potential to induce durable antitumor immunity. Adoptive T cell therapies, employing neoantigen-specific T cells expanded ex vivo, show promising results in eliminating otherwise resistant tumors. These clinical efforts reflect a growing commitment to bridging computational neoantigen predictions with patient-centered outcomes.

Despite remarkable progress, challenges persist in the neoantigen prediction arena. Variability in tumor mutation burden across cancer types influences the abundance of targetable neoantigens, with some tumors exhibiting low mutational loads that limit therapeutic targets. Additionally, accurate prediction of peptide-MHC binding remains computationally intensive and imperfect, partly due to the vast genetic diversity of HLA alleles. Immunosuppressive tumor microenvironments and antigen processing abnormalities can further impede the presentation and recognition of neoantigens, hindering immune activation.

Addressing these hurdles requires continuous refinement of bioinformatics pipelines, incorporating machine learning techniques that improve predictive accuracy by learning from experimental and clinical data. Multi-omics integration—combining genomics, transcriptomics, proteomics, and epigenomics—provides a holistic view of tumor biology, offering new layers of insight into antigen presentation and immunogenicity. Moreover, advances in single-cell sequencing and spatial transcriptomics promise to unravel the complexity of tumor-immune interactions, shedding light on the contextual factors influencing therapy response.

The future of neoantigen-based cancer immunotherapy is intertwined with innovations in computational biology and experimental validation. Open-access databases and collaborative networks accelerate data sharing, strengthening the knowledge base necessary for algorithm training and validation. Personalized medicine will benefit from streamlined pipelines that reduce turnaround times and costs, enabling real-time adaptation of immunotherapies based on tumor evolution and patient responses. This dynamic approach anticipates overcoming immune escape mechanisms and improving long-term treatment efficacy.

Notably, the development of neoantigen vaccines and T cell therapies underscores the importance of patient-specific approaches over conventional, broadly targeted treatments. By focusing on unique tumor antigens, these therapies minimize off-target effects and reduce collateral damage to normal tissues. The paradigm shift toward personalized immunotherapy exemplifies the cutting edge of oncology, representing a convergence of computational science, molecular biology, and clinical innovation.

Furthermore, neoantigen identification has broad implications beyond treatment, extending into cancer diagnostics and prognostics. Monitoring neoantigen-specific T cell responses can inform disease progression and therapy effectiveness, aiding clinicians in treatment decisions. As bioinformatics tools evolve, they may also assist in uncovering novel biomarkers predictive of immunotherapy response, facilitating patient stratification and clinical trial design.

Amid this promising landscape, ethical and regulatory considerations surrounding personalized immunotherapy require careful navigation. Data privacy, equitable access to cutting-edge treatments, and the management of treatment-related toxicities are critical factors influencing the clinical translation of neoantigen-based approaches. Multidisciplinary collaboration among bioinformaticians, immunologists, clinicians, and policymakers will be essential to ensure that technological innovations translate safely and effectively into patient care.

In summary, the confluence of evolving computational methods and experimental validation strategies marks a new era in cancer immunotherapy focused on neoantigen targeting. By bridging genomic insights with immune activation mechanisms, researchers and clinicians are forging a path toward highly tailored, effective, and enduring cancer treatments. Continued investment in bioinformatics tool development and integrated multi-omics approaches will be crucial to fully unlocking the therapeutic potential of neoantigens. This strategy holds promise not only for improving survival rates but also for fundamentally transforming the management of cancer worldwide.

Subject of Research: Computational prediction and validation of tumor-specific neoantigens for personalized cancer immunotherapy.

Article Title: Computational neoantigen prediction for cancer immunotherapy.

Article References:
Tejaswi, L., Ramesh, P., Aditya, S. et al. Computational neoantigen prediction for cancer immunotherapy. Genes Immun (2025). https://doi.org/10.1038/s41435-025-00365-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41435-025-00365-z

Carbohydrate antigens like STn have traditionally been viewed as elusive targets because their native structures are susceptible to enzymatic degradation and tend to elicit weak immune responses dominated by B-cell activity without potent T-cell engagement. Previous vaccine candidates such as Theratope® attempted to exploit STn antigens but ultimately failed to produce enduring clinical benefits, primarily due to insufficient immunogenic potency and rapid metabolic degradation. The present study innovates by chemically altering the fundamental glycosidic bond within STn, substituting the naturally labile O-glycosidic linkage with a more stable synthetic N(OMe)-glycosidic bond, thereby enhancing the antigen’s metabolic resilience and immunogenicity.

The concept of modifying the glycosidic linkage itself departs radically from conventional approaches that focus on acyl group alterations or other peripheral chemical modifications of carbohydrate antigens. By specifically targeting the bond that connects the sugar moiety to serine or threonine residues in the peptide backbone, the researchers protected the vaccine antigen from enzymatic cleavage without compromising its three-dimensional conformation essential for immune recognition. This meticulous chemical engineering maintains antigen authenticity, enabling the immune system to mount a cross-reactive response with the native STn found on tumor cells.

Experimental evaluation revealed that the N(OMe)-STn conjugated to keyhole limpet hemocyanin (KLH), a highly immunogenic carrier protein, elicited robust and selective immune activation. Notably, this conjugate exhibited heightened resistance to enzymatic hydrolysis, thus persisting longer in vivo to drive sustained immune engagement. Immune profiling demonstrated an impressively balanced Th1/Th2 T-cell response, critical for orchestrating both cellular and humoral immunity. This balanced immune activation contrasts with previous carbohydrate vaccines that often failed to induce significant T-helper cell involvement, a prerequisite for durable and effective antitumor immunity.

In vivo studies further substantiated the vaccine’s potency, showcasing significant antitumor effects manifested by prolonged survival and notable reduction in metastatic lesions in murine cancer models expressing native STn antigens. The vaccine’s mechanism extends beyond antibody generation, as it induced functional antibodies capable of mediating complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), two key effector functions that lead to tumor cell lysis and clearance. This dual mode of action highlights the comprehensive anti-cancer potential encompassing both direct tumor killing and facilitation of immune system engagement.

The implications of this research are profound, in part because STn expression is characteristic of several aggressive carcinomas, including breast, ovarian, and gastrointestinal cancers. The failure of past vaccine efforts illuminated the pressing need for antigen designs that overcome immune tolerance and elicit high-affinity, T-cell dependent antibody responses. By harnessing an unprecedented chemical modification strategy at the glycosidic linkage, this vaccine candidate transcends those limitations, offering a versatile platform that can be adapted for other TACA-based vaccines, potentially revolutionizing the field of carbohydrate antigen vaccine development.

Furthermore, the study exemplifies how chemical biology and immunology can intersect to solve longstanding obstacles in vaccine science. The meticulous synthetic chemistry required to create the N(OMe)-glycosidic bond, coupled with sophisticated immunological assays, underscores the multidisciplinary nature of this breakthrough. This approach not only protects the antigen from degradation but also fine-tunes its immunological presentation, ensuring that the immune system perceives the modified sugar as a genuine pathogenic marker while generating broadly cross-reactive antibodies.

One of the most compelling aspects of this vaccine design is its potential as a generalizable strategy—denoted as Modification of Carbohydrate Antigen Structures (MCAS)—that can be extended beyond STn. Such an approach could enable the development of vaccines targeting a variety of TACAs associated with different tumor types, addressing a critical bottleneck in the field where the immunogenic weakness of carbohydrate antigens has limited clinical translation. The ability to chemically engineer glycosidic linkages opens new avenues for the design of tailored vaccines that maintain antigen authenticity while enhancing immune recognition.

This research also provides valuable insights into the importance of glycosidic bond stability in antigen processing and presentation. Enzymatic cleavage of native O-glycosidic linkages has been an underappreciated hurdle in effective antigen persistence, and this work elegantly demonstrates that chemical stabilization at this site can profoundly affect vaccine efficacy. By preserving antigen integrity, the modified vaccine ensures longer exposure to immune cells, thereby facilitating improved antigen presentation via major histocompatibility complex (MHC) molecules and subsequent T-cell activation.

Additionally, the balanced induction of both Th1 and Th2 responses observed in vaccinated models is notable because it optimizes the orchestration of cell-mediated and antibody-mediated immunity. Th1 responses promote cytotoxic T lymphocyte activity critical for attacking tumor cells, while Th2 responses bolster antibody production, including IgG subtypes instrumental in CDC and ADCC. This equilibrium is crucial to achieving potent and sustained antitumor effects without inducing immune tolerance or dysfunction.

Beyond the scientific implications, the translational potential of the N(OMe)-STn–KLH conjugate vaccine is substantial. Given the demonstrated enhanced stability, immunogenicity, and functional antibody induction, this candidate is well-positioned for advancement into clinical development pipelines. The work also underscores the importance of integrating chemical design with immunological evaluation to overcome intrinsic biological barriers in vaccine technology.

In summary, the pioneering work by Ye and colleagues heralds a new era in carbohydrate antigen-based cancer vaccines by chemically reinforcing the glycosidic bonds vulnerable in natural antigens. This strategy not only surmounts prior hurdles associated with poor immunogenicity and rapid degradation but also establishes a blueprint adaptable to other challenging tumor markers. With robust preclinical efficacy and a mechanism supported by detailed biochemical and immunological rationale, this novel vaccine design invigorates hope for more effective immunotherapies against devastating STn-expressing cancers.

Subject of Research: Cells

Article Title: A cancer vaccine based on N-linked sialyl-Tn antigen elicits robust and selective antitumor immunity

Web References: http://dx.doi.org/10.1016/j.glycos.2025.100006

Image Credits: Xin-Shan Ye, et al

Keywords: Cancer, Immunology, Vaccine research, Medical cybernetics